AXP
0.018
38.5%
ZNO
0.093
-40%
APL
0.15
36.4%
RAN
0.002
-33.3%
TMKDD
0.15
36.4%
TPG
3.8
-32.1%
BIT
0.004
33.3%
CMG
0.13
-23.5%
GAS
0.03
30.4%
RWD
0.039
-20.4%
MTB
0.014
27.3%
8IH
0.018
-18.2%
CAV
0.005
25%
NVA
1.195
-17.6%
FBM
0.064
23.1%
AKN
0.005
-16.7%
EGR
0.545
22.5%
AVL
0.01
-16.7%
HAR
0.165
22.2%
IPT
0.005
-16.7%
RCR
0.017
21.4%
SHP
0.03
-16.7%
OM1
0.023
21.1%
VAR
0.005
-16.7%
HE8
0.012
20%
RXL
0.38
-16.5%
LGM
0.25
19%
REC
0.016
-15.8%
IS3
0.019
18.8%
BLG
0.011
-15.4%
KFM
0.09
18.4%
IRI
0.305
-15.3%
CHR
0.1
17.6%
AVE
0.006
-14.3%
NXD
0.41
17.1%
BNL
0.006
-14.3%
AHK
0.525
16.7%
M4M
0.006
-14.3%
MGU
0.007
16.7%
PLC
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PYC Therapeutics (ASX:PYC): Reports vision improvement in multiple RP11 patients

PYC Therapeutics (ASX:PYC) has developed the only clinical-stage investigational drug candidate designed specifically for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11).

👁️ PYC recently reported an improvement in vision in 2 patients with RP11
📣 PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024
🧪 PYC is now preparing for a registrational trial that will be designed to support a new drug application and commercial launch of this drug candidate 4

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240812/pdf/066j27mrjnft47.pdf